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Methods: This was a placebo-controlled double-blind study. Subjects were randomized to
400mg/kg (n5 127), 200mg/kg (n5 135) IGIV, or to 0.25% human albumin (n5 121) administered
every 2 weeks 6 7 days for 18 months.
Results: Elevated risk ratios of IGIV versus placebo included chills (3.85) in 9.5% of IGIV-treated
subjects (all doses), compared to 2.5% of placebo-treated subjects, and rash (3.08) in 15.3% of IGIV-
treated subjects versus 5.0% of subjects treated with placebo. Subjects in the highest IGIV dose group
had the lowest proportion of SAEs considered related to product (2 of 127 [1.6%]). Subjects treated
with IGIV experienced a lower rate of respiratory and all other infections compared to placebo.
Discussion: IGIV-treated subjects did not experience higher rates of renal failure, lung injury, or
thrombotic events than the placebo group. There were no unexpected safety findings. IGIV was
well tolerated throughout 18 months of treatment in subjects aged 50–89 years.
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drome, chronic inflammatory demyelinating polyneuropathy,
multifocal motor neuropathy, myasthenia gravis, and stiff per-
son syndrome [1]. IGIVexerts immune modulatory and anti-Components of this article were included in an abstract and poster pre-
sented at American Academy of Allergy, Asthma and Immunology
(AAAAI), Houston, TX, February 20–14, 2015.
An article focused on the primary outcome measure of this study, the ef-
ficacy of IGIV treatment in Alzheimer patients, is currently under review.
The current article is unique in scope in that it focuses on safety results only.
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Alzheimer’s disease (AD). Human sera from normal donors
contain antibodies to amyloid beta (Ab) protein [2], which
were shown to be neuroprotective in vitro [3]. Antibodies pu-
rified from human IGIV products reduced amyloid levels in
the central nervous system when infused in Ab transgenic
mice [4]. IGIV was therefore considered a promising agent
in passive immunotherapy because it contains naturally occur-
ring polyclonal human antibodies that bind to Ab aggregates,
foster the dissolution of Ab fibrils, and enhance microglia-
mediated phagocytosis of amyloid deposits in vitro [5–7].
Previous early-phase, investigator-initiated clinical studies
suggested that IGIVmight halt or reverse symptomsofdemen-
tia in subjects with mild-to-moderate AD [8–11]. For this
reason, a large randomized, placebo-controlled, phase 3 study
in mild-to-moderate ADwas initiated to test the safety and ef-
ficacy of 18 months of IGIV treatment at 200 or 400 mg/kg/
2 wks [12,13]. There were 262 subjects exposed to IGIV,
and 121 subjects exposed to human albumin as a control.
IGIV has an established safety profile in children and
adults. Elderly subjects are treated with IGIV for both
labeled and unlabeled conditions [1,14]; however, there are
limited data available from appropriately placebo-
controlled, double-blinded studies on the safety of IGIV in
elderly patients, with most data derived from case studies
and retrospective studies [15–19]. IGIV has been
associated with uncommon but serious adverse events
(SAEs) for which the elderly carry an increased risk such
as thrombotic events, transfusion-related lung injury
(TRALI), and renal failure. Although the study described
in this report did not meet its primary or secondary efficacy
endpoints of reducing cognitive decline and preserving func-
tional abilities in AD [20], a substantial body of safety data
was amassed in one of the largest placebo-controlled studies
of intravenous immunoglobulin conducted in a geriatric
population [21,22].2. Methods
2.1. Study design and participants
This was a phase 3, randomized, double-blind, placebo-
controlled, two-dose arm study in elderly subjects with
mild-to-moderate AD. Subjects were enrolled in the study
at 45 centers within the Alzheimer’s Disease Cooperative
Study (ADCS, San Diego, CA) consortium in the United
States and Canada. Approximately 385 randomized subjects
were planned to be enrolled.
At screening, each subject underwent mini-mental state
examination (MMSE), as well as physical, neurological,
and laboratory assessments. Subjects were randomly as-
signed in a 1:1:1 ratio to one of three treatment arms to
receive infusions every 2 weeks for 70 weeks (a total of 36
infusions) as an add-on to conventional Food and Drug
Administration approved AD pharmacotherapy. The three
treatment arms were: IGIV 200 mg/kg, IGIV 400 mg/kg,and albumin placebo control at either 2 mL/kg or 4 mL/kg.
A concentration of 0.25% albumin was chosen to match the
volume, color, and foam-forming characteristics of the IGIV.
Clinical assessments were conducted every 3 months, and
magnetic resonance imaging (MRI)was done every 9months.
End-of-study assessments were performed at week 76. An in-
dependent data safety monitoring board performed safety
monitoring at regular intervals throughout the study.
Eligible participants of either gender were aged
50–89 years with a diagnosis of probable AD of mild-to-
moderate severity as determined by a score of 16–26 on the
MMSE scale. Subjects may have been receiving stable doses
of AD medication (acetylcholinesterase inhibitor and/or
memantine) for at least 12 weeks before screening and
required the participation of an able caregiver. The main
exclusion criteria were non-Alzheimer’s dementia, residence
in a skilled nursing facility, clinically significant cardiovascu-
lar disease, recent central or peripheral thrombosis and/or
thromboembolic disease, or active renal disease.
At the investigator’s discretion, subjectsmay have received
investigational product infusions at a clinic, home or other
suitable locations. Clinical and laboratory assessments were
conducted every 3 months until the end-of-study visit.
2.2. Safety outcome measures
Safety objectives included the proportion of subjects
experiencing: any adverse events (AEs), product-related
AEs, or serious adverse events (SAEs), the number of infu-
sions temporally associated (defined as during or within
72 hours of completion of an infusion) with AEs or SAEs,
infusions causally associated with AEs and/or SAEs, and in-
fusions discontinued, slowed, or interrupted due to an AE.
Also examined were the proportions of IGIV-treated sub-
jects experiencing a decrease in hemoglobin (.1.5 g/dL)
and clinically significant rash requiring systemic therapy.
2.3. Randomization and statistical analysis
Randomization was conducted using a stratified
permuted block method with an allocation ratio of 1:1:1. As-
signments to the three treatment groups were stratified by
site, APOE ε4 carrier status (Y/N), and disease severity as
defined by MMSE category (20, .20) at screening.
The sample size was powered for efficacy analyses,
which constituted the primary and secondary endpoints of
the study. The safety analysis set consisted of all subjects
who received study product (IGIV or albumin placebo).
Descriptive statistics (counts, percentages, and relative
risk) were used to summarize safety outcome measures.
Relative risk confidence intervals which were calculated us-
ing the approximation proposed by Katz et al. [23].
2.4. Role of the funding source
The study was conducted by Baxalta US Inc. in collabo-
ration with ADCS, a clinical trial consortium supported by
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Institutes of Health.3. Results
Of 390 subjects who met inclusion/exclusion criteria and
were randomized, 383 subjects received at least 1 dose of
study product (262 received IGIV and 121 received albumin
placebo) and were therefore part of the safety analysis data
set. Of the 390 randomized subjects, seven did not receive
treatment (two in the 400 IU/kg arm, three in the 200 IU/kg
arm, and two in the placebo arm). There were comparable
numbers of subjects who discontinued from each treatment
group (Fig. 1). Of the 81 subjects who discontinued, 26 dis-
continued because of an adverse event, 16 were unwilling
or unable to participate, 13 withdrew consent, seven had a
study partner unwilling or unable to participate, four subjects
died, two discontinued due to a protocol violation, and 13 dis-
continued for other reasons. An analysis of discontinuation
by high and low dose was conducted to examine the effect
of volume of infusion on discontinuation. Although there
were numerically more subjects who discontinued from the
low-dose (200 mg/kg) IGIV and low-dose (2 mL) placebo
treatment groups (24.7%) compared with the high-dose
(400 mg/kg) IGIV and placebo (4 mL) groups (17.3%), this
trend did not reach statistical significance (P 5 .081). Simi-
larly, the mean (SD) duration of treatment before withdrawal
was similar between the IGIV dose groups (223.3 [146.75]
days for high dose and 224.9 [138.61] days for low dose)
and the placebo groups (212.9 [157.61] for high dose and
263.3 [141.88] days for low dose).
The mean age of study participants was 70.3 years: 57%
of subjects were 65–80 years and 14% were .80 years,
whereas 29% were,65 years. Most of the subjects were fe-
male (54.6%), and 60% of subjects had mild severity AD
(MMSE score 5 21–26) and 40% had moderate severity
AD (MMSE score 5 16–20). Most subjects were APOE
ε4 carriers (68.2%), and 17.7% of subjects were homozy-
gous APOE ε4/ε4. Disease characteristics were evenly
balanced across the treatment groups (Table 1).Fig. 1. Flow chart of subject disposition. 390 subjects were randomized and 383 su
treatment groups: IGIV 400 mg/kg (n 5 127), 200 mg/kg (n 5 135), and albuminThe median number of IGIV infusions/subject was 36 in
the 400 mg/kg arm, 35 in the 200 mg/kg arm, and 35 in the
combined placebo arms. Total exposure to IGIV/subject was
915.6 g in the 400 mg/kg cohort and 468.0 g in the
200 mg/kg cohort. As expected, at the month 18 assessment,
serum levels of IgG were elevated in a dose dependent
manner compared to baseline (Table 2). Levels of IgG in
the cerebrospinal fluid (CSF) were also found to increase
from baseline in a dose dependent manner in subjects treated
with IGIV compared to the placebo arm (Table 2).
There were nine subjects who experienced SAEs consid-
ered related or probably related to IGIV, including 2 of 127
(1.6%) subjects in the high-dose group and 7 of 135 (5.2%)
subjects in the low-dose group compared to 4 of 121 (3%)
subjects in the albumin control group. IGIV-related SAEs
in the high-dose group included congestive cardiac failure,
myocardial infarction, and vasogenic cerebral edema; in
the low-dose group, related SAEs included anaphylactic re-
action, blood pressure increased, hemoglobin decreased, ce-
rebral hemorrhage, partial seizures, mental status changes,
and pulmonary embolism; and in the placebo group, the
related SAEs included congestive cardiac failure, pyrexia,
pulmonary embolism, and deep vein thrombosis (two cases).
A lower percentage of subjects in the highest dose group
experienced any SAE (16.5%) compared to the 200 mg/kg
dose group (23.7%) and the combined placebo group
(21.5%; Table 3).
Subjects were monitored for the known labeled risks of
IGIV throughout this study. Of the related SAEs mentioned
above, 1 case of anaphylaxis (resolved) occurred during an
infusion of IGIV. No TRALI or respiratory failure occurred
during the study. One subject, a 74-year-old female
receiving 200 mg/kg, experienced a nonserious AE of cere-
bellar infarction. There were 2 female subjects who experi-
enced myocardial infarction: a 72-year-old in the placebo
group and a 77-year-old in the 400-mg/kg dose group. The
proportion of subjects with thromboembolic events was
lower in the IGIV treatment groups compared to the placebo
group: (5/262 [1.9%] vs. 6/121 [5%]). Five subjects experi-
enced new or worsening renal failure, including two in thebjects were treated (and therefore included in the safety population) in three
placebo (n 5 121). A total of 262 subjects were exposed to IGIV.
Table 1
Baseline demographics and disease characteristics overall and by treatment arm (Intent-to-treat population)
Demographic or baseline characteristic 400 mg/kg IGIV (N 5 129) 200 mg/kg IGIV (N 5 138) Placebo (N 5 123) All (N 5 390)
Age (y)
N 129 138 123 390
Mean (SD) 70.6 (9.7) 70.1 (8.3) 70.2 (9.9) 70.3 (9.3)
Median (range) 71.0 (50–89) 71.0 (53–87) 70.0 (50–88) 71.0 (50–89)
Weight (kg)
N* 128 137 121 386
Mean (SD) 71.0 (14.7) 72.4 (13.5) 72.7 (16.6) 72.1 (14.9)
Median (range) 71.8 (40.0–111.0) 73.5 (46.0–106.4) 71.4 (44.7–123.0) 72.0 (40.0–123.0)
Education (y)
N 129 138 123 390
Mean (SD) 15.3 (2.9) 15.7 (3.2) 15.4 (3.0) 15.5 (3.0)
Median (Range) 16.0 (6–20) 16.0 (8–20) 16.0 (6–20) 16.0 (6–20)
MMSE total scorey
N 129 138 123 390
Mean (SD) 21.3 (3.2) 21.5 (3.1) 21.1 (3.2) 21.3 (3.2)
Median (range) 22.0 (16–26) 22.0 (16–26) 21.0 (16–26) 22.0 (16–26)
Gender, n (%)
Male 59 (45.7) 61 (44.2) 57 (46.3) 177 (45.4)
Female 70 (54.3) 77 (55.8) 66 (53.7) 213 (54.6)
Race, n (%)
White 128 (99.2) 133 (96.4) 120 (97.6) 381 (97.7)
Black 1 (0.8) 4 (2.9) 1 (0.8) 6 (1.5)
Asian 0 1 (0.7) 0 1 (0.3)
Otherz 0 0 2 (1.6) 2 (0.5)
Ethnicity, n (%)
Hispanicx 3 (2.3) 4 (2.9) 5 (4.1) 12 (3.1)
Non-Hispanic 126 (97.7) 134 (97.1) 115 (93.5) 375 (96.2)
Otherjj 0 0 3 (2.4) 3 (0.8)
AD severity, n (%)
Mild 83 (64.3) 83 (60.1) 68 (55.3) 234 (60.0)
Moderate 46 (35.7) 55 (39.9) 55 (44.7) 156 (40.0)
Concomitant AD treatment at baseline, n (%)
AChEl{ 117 (91) 124 (90) 112 (91) 353 (90.5)
Memantine 96 (74) 103 (75) 92 (75) 291 (74.6)
AChEl or memantine 126 (98) 137 (99) 120 (98) 383 (98.2)
None 3 (2) 1 (1) 3 (2) 7 (1.8)
APOE ε4 carrier and homozygous allele/
genotype, n (%)
Yes 87 (67.4) 94 (68.1) 85 (69.1) 266 (68.2)
APOE ε4/ε4 23 (17.8) 24 (17.4) 22 (17.9) 69 (17.7)
*Some subjects were missing body weight measurements at baseline.
yMMSE score at screening; inclusion criterion range 5 16–26 where lower scores indicate greater impairment.
zOther includes: American Indian or Alaska Native, multiple, unknown, and not reported.
xHispanic includes: Hispanic and Latino.
jjOther includes: unknown and not reported.
{AChEI 5 acetylcholinesterase inhibitor.
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(0.7%), and two in the placebo group (1.7%).
Although hemolysis is a labeled risk, there were no AEs
of hemolysis. There were, however, three AEs of low hemo-
globin. An assessment of clinical laboratory results showed
that a greater number of subjects in the IGIV treatment
groups than the placebo group experienced a drop in hemo-
globin.1.5 g/dL between consecutive visits: 24.4% of sub-
jects receiving 400 mg/kg and 17.8% of subjects receiving
200 mg/kg compared to 13.2% subjects receiving placebo
(Table 4). There were no clinical signs linking this decrease
in hemoglobin to hemolysis, as LDH was in the normal ornear-normal range for all subjects. Furthermore, an increase
in hemoglobin .1.5 g/dL between consecutive visits was
also observed in some subjects, with slightly more occurring
in the IGIV treatment groups compared to placebo. A review
of anti-A and anti-B isoagglutinin titers present in the
batches of IGIVused in this study was conducted. The high-
est titer of anti-A was 1:16 and all anti-B titers were lower
than 1:16; well below the limit of 1:64 recommended by
the European Pharmacopeia (using 2.6.20 Method B) [24].
Rashes requiring systemic treatment or discontinuation of
an infusion were a safety outcome measure of the study. Five
subjects in the IGIV treatment groups experienced a rash
Table 2
Exposure to IGIV
Time point Arm
Serum levels of IgG
(g/L)
CSF levels of IgG
(mg/dL)
n Mean (SD) n Mean (SD)
Baseline 400 mg/kg 127 9.9 (2.0) 8 2.20 (1.01)
200 mg/kg 134 9.9 (2.2) 10 1.90 (0.96)
Placebo 119 9.7 (2.6) 17 2.54 (1.33)
18 months 400 mg/kg 100 17.2 (3.5) 8 5.36 (4.77)
200 mg/kg 99 13.6 (2.5) 10 2.77 (1.44)
Placebo 93 9.6 (2.4) 17 2.52 (1.43)
NOTE. Safety data are presented descriptively without statistical testing.
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subjects in the 400 mg/kg group and two subjects in the
200-mg/kg group. In contrast, no subjects in the placebo
group experienced a rash requiring discontinuation of the
infusion. A greater percentage of subjects in the IGIV treat-
ment groups (35 of 262 [13.4%]) experienced a rash
requiring systemic therapy (diphenhydramine, cortisone,
dexamethasone, loratadine, prednisone, methylpredniso-
lone, or cetirizine) than in the placebo group (8/121 [6.6%]).
There were not a greater number of deaths in the IGIV
treatment groups compared to placebo. There were four
deaths in 263 subjects in the IGIV treatment groups
(including one subject treated with 400 IU/kg who had a
possibly related congestive cardiac failure), and three subjects
treated with 200 IU/kg (one case of possibly related cerebral
hemorrhage; and two cases of multiorgan failure [one case
not related and one case unlikely related]). There were two
deaths in 121 subjects in the placebo group (not related meta-
static colon cancer and possibly related pulmonary embolism).
The nonserious AEs that occurred in the highest number
of subjects in the combined IGIV treatment groups were
headache (24.0%), hypertension/blood pressure increased
(22.9%), fall/contusion/laceration (18.3%), rash (15.3%),
infusion site extravasation (14.5%), and diarrhea (14.1%).
When compared to the incidence of nonserious AEs in the
placebo group, only AEs of chills and rash exhibited statis-
tically significant elevated risk ratios for IGIV treatmentTable 3
Number of subjects (%) with serious AEs and AEs of interest
400 mg/kg, n 5
Any AEs 124 (97.6)
SAEs 21 (16.5)
SAEs related to study product 2 (1.6)
Deaths during or after treatment 1 (0.8)
Subjects hospitalized due to an AE 18 (14.2)
Rash requiring systemic therapy* 19 (15.0)
New or worsening renal failure 2 (1.6)
Thromboembolic events 2 (1.6)
Myocardial infarction, stroke, arterial thrombosis 1 (0.8)
Upper respiratory infections 16 (12.6)
*Diphenhydramine, cortisone, dexamethasone, loratadine, prednisone, methylp(3.85 [95% CI, 1.18–12.50] and 3.08 [95% CI, 1.34–7.07],
respectively). The rates per subject for chills were 9.5% in
subjects receiving IGIV (all doses) versus 2.5% in those
receiving placebo, and for rash, they were 15.3% versus
5.0%. Neither of these AEs were unexpected. Statistically
significant declines in risk were noted for combined AEs
of fall/contusion/laceration (0.67 [95% CI, 0.46–0.99]) and
bradycardia (0.29 [95% CI, 0.10–0.86]). As would be ex-
pected, subjects treated with IGIV reported fewer infections
than did subjects treated with placebo (34.0% versus 47.9%).
Instances of upper respiratory infections were also lower
among those receiving IGIV compared to placebo (15.2%
vs. 23.1%). An analysis of all AEs of infections demon-
strated a lower relative risk for subjects receiving IGIV
(0.71 [95% CI, 0.55–0.91]; Fig. 2).
Analyses of AEs and SAEs determined that percentages
of infusions temporally or causally associated with AEs
and/or discontinued or slowed due to an AE were similar
whether IGIV or placebo was administered. For example,
there were 396 of 3883 (10.2%), 467 of 3954 (11.8%), and
349 of 3691 (9.5%) infusions temporally associated with
AEs and/or SAEs in the 400 IU/kg, 200 IU/kg, and placebo
arms, respectively. Causally associated AEs and/or SAEs
were reported in 225 of 3883 (5.8%), 265 of 3954 (6.7%),
and 172 of 3691 (4.7%) infusions in the 400 IU/kg, 200
IU/kg, and placebo arms, respectively. The proportion of in-
fusions discontinued, slowed or interrupted due to an AE/
SAE were 48/3883 (1.2%), 28/3954 (0.7%), and 36/3691
(1.0%), respectively.
Subjects received an MRI for dual purposes of clinical
safety assessment and volumetric measurements at scre-
ening, month 9, and month 18, or at the termination visit
in the case of an early termination. One SAE of vasogenic
asymptomatic cerebral edema (amyloid-related imaging
abnormalities-E [ARIA-E]) was reported in a subject treated
with 400-mg/kg IGIV. Approximately 10% of subjects
developed treatment emergent cerebral microhemorrhages
(amyloid-related imaging abnormalities-H [ARIA-H]), which
was similar across all treatment groups. However, when
examined by APOE ε4 status, APOE ε4 carrier subjects127 200 mg/kg, n 5 135 Placebo, n 5 121
133 (98.5) 117 (96.7)
32 (23.7) 26 (21.5)
7 (5.2) 4 (3)
3 (2.2) 2 (1.7)
26 (19.3) 23 (19.0)
16 (11.9) 8 (6.6)
1 (0.7) 2 (1.7)
3 (2.2) 6 (5.0)
1 (0.7) 1 (0.8)
24 (17.8) 28 (23.1)
rednisolone, or cetirizine.
Table 4
Changes in hemoglobin level
N (%) IGIV, 400 mg/kg, n 5 127 IGIV, 200 mg/kg, n 5 135 All placebo doses, n 5 121
Subjects with decrease in hemoglobin .1.5 g/dL 31 (24.4) 24 (17.8) 16 (13.2)
Subjects with increase in hemoglobin .1.5 g/dL 17 (13.4) 16 (11.9) 12 (9.9)
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riers both in the IGIVand placebo groups (Table 5). As themi-
crohemorrhages were identified in routine scans and were
asymptomatic, most microhemorrhages in the above analysis
were not considered AEs by the investigators. The percentage
of subjects (9 of 262 [3.4%]) in whom cerebral microhemor-
rhage was reported as an AE in the combined IGIV treatment
group was similar to that in the placebo group (4 of 121
[3.3%]).4. Discussion
Biweekly treatment with Gammagard Liquid (IGIV; 200
or 400 mg/kg) over 18 months in patients with AD of mild-
to-moderate severity was well tolerated in a special (geri-
atric) population aged 50 to 89 years, with relatively few
adverse events in either the placebo or active IGIV dose
groups [25]. To date, limited information has been collected
in controlled clinical trials about geriatric use of IGIV. TheFig. 2. Incidence (%) and risk ratio of AEs in subjects treated with IGIV. Risk ratio
treatment group is displayed in the forest plot. Ratios .1 represent higher risk tha
(CIs) were computed based on the method by Katz et al. [23]. Similar AEs were co
fall/contusion/laceration. The incidence values (%) are based on 262 subjects treapresent study offered an opportunity to examine the safety
of IGIV in a large (N 5 390) sample of elderly patients.
Geriatric patients are considered to have an elevated risk of
acute renal failure and arterial or venous thrombosis during
IGIV treatment [15,25,26]. Subjects with significant cardiac
conditions, thrombosis and or thromboembolic disease, or
renal disease were therefore excluded from the study. The
IGIV product used in this study does not contain sucrose,
which has been demonstrated to be associated with renal
complications [27]. Only five subjects experienced new or
worsening renal failure, and they were distributed between
the three studyarms.Theproportion of subjectswith thrombo-
embolic events was also lower in the IGIV treatment groups
compared to the placebo group: (1.9% vs. 5.0%). The occur-
rence of thrombotic events has been considered one of the
most serious health risks of IGIV products. In a recent publi-
cation of a retrospective cohort study, Daniel et al. compared
the safety profiles of six IGIV products in 11,785 patients
[28,29]. Of all six products studied, Gammagard Liquid(indicated in forest plot above by diamonds) for AEs with respect to placebo
n placebo group. Ratios ,1 represent lower risk. 95% confidence intervals
mbined, including all infections; hypertension/blood pressure increased; and
ted with at least one infusion of IGIV.
Table 5
Emergent intracerebral microhemorrhages at month 18 by APOE ε4 status
APOE ε4 carrier? Change in microhemorrhages since baseline All doses IGIV subjects (%) Placebo all doses subjects (%)
Yes No additional hemorrhage 118/133 (88.7) 58/68 (86.6)
Additional hemorrhage 15/133 (11.3) 9/68 (13.4)
No No additional hemorrhage 56/59 (94.9) 26/26 (100.0)
Additional hemorrhage 3/59 (5.1) 0/26 (0.0)
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cases per 1000 patients exposed) compared to the overall rate
of 10.4 cases of same-day thrombotic events per 1000 patients
exposed. The authors used Gammagard Liquid IGIV as the
reference for analysis of odds ratios for same-day thrombotic
event occurrence in all of the other IGIV products, because it
had the lowest incidence of thrombotic events. In the present
study, one SAE of asymptomatic vascular cerebral edemawas
reported in a subject treated with 400-mg/kg IGIV (a subse-
quent MRI demonstrated that the edema was resolved). This
reflects approximately 0.4% of treated subjects, which is
lower than the incidence of vasogenic edema which was re-
ported in approximately 10% of AD subjects in a phase 1 trial
of bapineuzumab [30].
The Alzheimer’s Association Research Roundtable Work-
group recommends careful MRI monitoring for the occur-
rence of ARIA in clinical studies of amyloid modifying
therapeutic agents [31]. Most subjects did not have additional
microhemorrhages at month 18 according to MRI examina-
tion. The recent study reported by Dodel et al [32] using
another intravenous immunoglobulin product (Octapharma)
reported more patients experiencing microbleeds (the term
that team used for “microhemorrhages” as they were referred
to in our study), (20%) compared to those receiving placebo
(7%). This is unlike the results of our study where the rate of
new cerebral microhemorrhages observed was similar among
the treatment arms (approximately 10%). However, the rate
was numerically increased in subjects who are APOE ε4 car-
riers. The relative safety of IGIV with regard to neurologic
adverse events (particularly cerebral microhemorrhage or
stroke) is notable considering that levels of total IgG anti-
bodies were observed to have increased dose dependently
in CSF at the 18-month assessment, indicating that IgG had
crossed the blood-brain barrier.
A documented potential risk of treatment with IGIV is he-
molysis [33–37]. There were no AEs of hemolysis reported
during the study. Decrease in hemoglobin (.1.5 g/dL) was
defined as significant in the protocol; however, only three
subjects experienced a clinically significant decrease in
hemoglobin that was reported as an AE in the study. There
were a greater number of subjects in the IGIV treatment
groups experiencing a drop in hemoglobin .1.5 g/dL
between consecutive visits compared to subjects receiving
placebo. The decline in hemoglobin was mild to moderate,
and no specific mechanism for the decline was identified.
The higher rate of subjects with a substantial drop
in hemoglobin levels in the 400-mg/kg group might beattributable to the fact that more of these subjects had a
,1:3 ratio of iron to iron binding capacity at baseline
compared to those in the two other study groups (data not
shown). There were no clinical signs linking this decrease
in hemoglobin to hemolysis, as LDH was in the normal or
near-normal range for all subjects. Furthermore, analysis
of isoagglutinins anti-A and anti-B in Gammagard Liquid
IGIV demonstrate that the product has titers lower than the
1:64 recommended by the European Pharmacopoeia by at
least 2-step dilution (the highest titer of anti-A was 1:16
and all anti-B titers were lower than 1:16).
When compared to the incidence of nonserious AEs in the
placebo treatment group, only chills and rash exhibited sta-
tistically significant risk ratios for IGIV, 10% treatment
(Fig. 2). Although IGIV treatment was associated with an
elevated risk of rash, pre-treatment of subjects who experi-
enced allergic reactions with antihistamine was permitted
in the study protocol to protect them from further reactions.
This approach may permit patients to be treated who would
otherwise be unable to receive IGIV.
The most common adverse event in subjects treated with
IGIV was headache, a known risk of IGIV [25,38]. However,
there was not an elevated risk ratio for headache because
patients receiving placebo had a similar incidence.
Beneficial decreases in infection rate and falls (Fig. 2) were
observed with IGIV treatment. The reduction of infections
may be accounted for by the protective effect of IGIV, 10%,
which is well established in primary immunodeficiency [25].
Although no subjects had an IgG titer considered abnormally
low, many subjects were on the lower limit of normal at base-
line; 8.1% of subjects had an IgG concentration,7 g/L (data
not shown), which suggests that their adaptive immune
response to pathogen may have been limited and that supple-
mentation with IGIV may reduce the infection rate in the
elderly. Even elderly subjects with a normal IgG titer may
exhibit reduced opsonophagocytic activity and low antibody
avidity. Such a diminution of endogenous antibody function
with age has been reported andmay account for decreased vac-
cine efficacy [39]. Multiple lymphoid lineages may undergo
changes in the elderly contributing to immunosenescence
[40,41]. The reasons for IGIV infusion in a geriatric patient
can be multifarious, ranging from chemotherapy support, to
autoimmune disease and solid organ transplantations. This
clinical trial was the first large, controlled study of IGIV in
this unique patient population. Its results demonstrated IGIV
to be safe and comparable in AE incidence rates to albumin
infusion in the elderly.
D. Gelmont et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2 (2016) 131-139138Allergic/hypersensitivity reactions, hemolysis, TRALI,
renal failure, and thrombotic/thromboembolic events are
all considered risks with IGIV treatment, particularly in
elderly patients, however in this placebo-controlled study,
IGIV was found to be well tolerated and safe, with no new
safety findings or unexpected AEs. Furthermore, patients
treated with IGIV demonstrated a significantly lower risk ra-
tio for infections and falls/lacerations/contusions, which
could be a potentially important finding if demonstrated in
a controlled clinical trial, considering the risks associated
with falls in the geriatric population. The previously estab-
lished safety record of IGIV has been confirmed in the pre-
sent controlled analyses in a large geriatric population.
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1. Systematic review: The literature was searched for
articles and abstracts using PubMed and Embase.
Most publications on IGIV use in the elderly were
case studies, with few randomized, placebo-
controlled, double-blinded studies.
2. Interpretation: The results of this study indicate that
long-term IGIV treatment in an elderly population
was safe and well tolerated.
3. Future directions: The reduction of infections in sub-
jects treated with IGIV suggests that there is a need to
assess secondary hypogammaglobulinemia and the
functionality and avidity of IgG in the elderly popu-
lation. Falls, lacerations, and contusions are common
in geriatric patients and are associated with
morbidity and mortality. If the role of IGIV in
reducing the rate of this complication can be
confirmed, the mechanism of action should be inves-
tigated. More safety data should be collected to
confirm the low risk of thromboembolic events and
hemolysis observed in this study.
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